{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:47:06Z","timestamp":1793044026003,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011033","name":"Thermo Fisher Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tumoroids, sometimes referred to as cancer organoids, are patient-derived cancer cells grown as 3D, self-organized multicellular structures that maintain key characteristics (e.g., genotype, gene expression levels) of the tumor from which they originated. These models have emerged as valuable tools for studying tumor biology, cytotoxicity, and response of patient-derived cells to cancer therapies. However, the establishment and maintenance of tumoroids has historically been challenging, labor intensive, and highly variable from lab to lab, hindering their widespread use. Here, we characterize the establishment and\/or expansion of colorectal, lung, head and neck, breast, pancreas, and endometrial tumoroids using the standardized, serum-free Gibco OncoPro Tumoroid Culture Medium. Newly derived tumoroid lines (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920) were analyzed by targeted genomic profiling and RNA sequencing and were representative of tumor tissue samples. Tumoroid lines were stable for over 250 days in culture and freeze-thaw competent. Previously established tumoroid lines were also transitioned to OncoPro medium and exhibited, on average, similar growth rates and conserved donor-specific characteristics when compared to original media systems. Additionally, OncoPro medium was compatible with both embedded culture in extracellular matrix and growth in a suspension format for facile culture and scale up. An example application of these models for assessing the cytotoxicity of a natural killer cell line and primary natural killer cells over time and at various doses demonstrated the compatibility of these models with assays used in compound and cell therapy development. We anticipate that the standardization and versatility of this approach will have important benefits for basic cancer research, drug discovery, and personalized medicine and help make tumoroid models more accessible to the cancer research community.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-86979-9","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T10:39:58Z","timestamp":1738319998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications"],"prefix":"10.1038","volume":"15","author":[{"given":"Colin D.","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Yankaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip","family":"Shahi Thakuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Balhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyanne","family":"Salen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Beam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chatman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybelle","family":"Djikeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu Jenny","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Dockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Bailey-Steinitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakhan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Dallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kuninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"86979_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/jnci\/djt007","volume":"105","author":"JP Gillet","year":"2013","unstructured":"Gillet, J. P., Varma, S. & Gottesman, M. M. The clinical relevance of cancer cell lines. J. Natl. Cancer Inst. 105, 452\u2013458 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"86979_CR2","doi-asserted-by":"publisher","first-page":"18708","DOI":"10.1073\/pnas.1111840108","volume":"108","author":"JP Gillet","year":"2011","unstructured":"Gillet, J. P. et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. U S A. 108, 18708\u201318713 (2011).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"86979_CR3","doi-asserted-by":"crossref","unstructured":"Domcke, S., Sinha, R., Levine, D. A.,  Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).","DOI":"10.1038\/ncomms3126"},{"key":"86979_CR4","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/s41467-019-10148-6","volume":"10","author":"K Liu","year":"2019","unstructured":"Liu, K. et al. Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data. Nat. Commun. 10, 2138 (2019).","journal-title":"Nat. Commun."},{"key":"86979_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13073-021-00888-w","volume":"13","author":"D Peng","year":"2021","unstructured":"Peng, D. et al. Evaluating the transcriptional fidelity of cancer models. Genome Med. 13, 73 (2021).","journal-title":"Genome Med."},{"key":"86979_CR6","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","volume":"24","author":"F Weeber","year":"2017","unstructured":"Weeber, F., Ooft, S. N., Dijkstra, K. K. & Voest, E. E. Tumor organoids as a pre-clinical cancer model for drug discovery. Cell. Chem. Biol. 24, 1092\u20131100 (2017).","journal-title":"Cell. Chem. Biol."},{"key":"86979_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-023-01154-7","author":"DM Stresser","year":"2023","unstructured":"Stresser, D. M. et al. Towards in vitro models for reducing or replacing the use of animals in drug testing. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-023-01154-7 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"86979_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s43018-022-00359-0","volume":"3","author":"B Herpers","year":"2022","unstructured":"Herpers, B. et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR \u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors. Nat. Cancer. 3, 418\u2013436 (2022).","journal-title":"Nat. Cancer"},{"key":"86979_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai, A., Bhola, P. & Welm, A. L. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 40, 26\u201335 (2022).","journal-title":"Cancer Cell."},{"key":"86979_CR10","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis, E., Kretzschmar, K. & Clevers, H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15, 3380\u20133409 (2020).","journal-title":"Nat. Protoc."},{"key":"86979_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933\u2013945 (2015).","journal-title":"Cell"},{"key":"86979_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","volume":"15","author":"CM Cattaneo","year":"2020","unstructured":"Cattaneo, C. M. et al. Tumor organoid-T-cell coculture systems. Nat. Protoc. 15, 15\u201339 (2020).","journal-title":"Nat. Protoc."},{"key":"86979_CR13","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41467-018-05190-9","volume":"9","author":"X Li","year":"2018","unstructured":"Li, X. et al. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. Nat. Commun. 9, 2983 (2018).","journal-title":"Nat. Commun."},{"key":"86979_CR14","doi-asserted-by":"crossref","unstructured":"Habowski, A. N. et al. Patient-derived models of cancer in the NCI PDMC Consortium: Selection, pitfalls, and practical recommendations. Cancers 16  (2024).","DOI":"10.3390\/cancers16030565"},{"key":"86979_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41563-021-01057-5","volume":"21","author":"BL LeSavage","year":"2022","unstructured":"LeSavage, B. L., Suhar, R. A., Broguiere, N., Lutolf, M. P. & Heilshorn, S. C. Next-generation cancer organoids. Nat. Mater. 21, 143\u2013159 (2022).","journal-title":"Nat. Mater."},{"key":"86979_CR16","doi-asserted-by":"publisher","first-page":"107588","DOI":"10.1016\/j.celrep.2020.107588","volume":"31","author":"KK Dijkstra","year":"2020","unstructured":"Dijkstra, K. K. et al. Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine. Cell. Rep. 31, 107588 (2020).","journal-title":"Cell. Rep."},{"key":"86979_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Comprehensive molecular characterization","year":"2012","unstructured":"Comprehensive molecular characterization. Of human colon and rectal cancer. Nature 487, 330\u2013337 (2012).","journal-title":"Nature"},{"key":"86979_CR18","unstructured":"inferCNV of the Trinity CTAT Project. https:\/\/github.com\/broadinstitute\/inferCNV"},{"key":"86979_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nm.3175","volume":"19","author":"A Sadanandam","year":"2013","unstructured":"Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619\u2013625 (2013).","journal-title":"Nat. Med."},{"key":"86979_CR20","unstructured":"The, N. C. I. Patient-Derived Models Repository (PDMR), NCI-Frederick, Frederick National Laboratory for Cancer Research."},{"key":"86979_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386e10 (2018).","journal-title":"Cell"},{"key":"86979_CR22","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ccell.2021.07.020","volume":"39","author":"V Veninga","year":"2021","unstructured":"Veninga, V. & Voest, E. E. Tumor organoids: Opportunities and challenges to guide precision medicine. Cancer Cell. 39, 1190\u20131201 (2021).","journal-title":"Cancer Cell."},{"key":"86979_CR23","doi-asserted-by":"publisher","first-page":"14262","DOI":"10.1038\/ncomms14262","volume":"8","author":"M Sch\u00fctte","year":"2017","unstructured":"Sch\u00fctte, M. et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat. Commun. 8, 14262 (2017).","journal-title":"Nat. Commun."},{"key":"86979_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1541-7786.MCR-18-0531","volume":"17","author":"I Romero-Calvo","year":"2019","unstructured":"Romero-Calvo, I. et al. Human organoids share structural and genetic features with primary pancreatic adenocarcinoma tumors. Mol. Cancer Res. MCR. 17, 70\u201383 (2019).","journal-title":"Mol. Cancer Res. MCR"},{"key":"86979_CR25","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","volume":"10","author":"M Kim","year":"2019","unstructured":"Kim, M. et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat. Commun. 10, 3991 (2019).","journal-title":"Nat. Commun."},{"key":"86979_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-023-02809-8","volume":"42","author":"L Thorel","year":"2023","unstructured":"Thorel, L. et al. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma. J. Exp. Clin. Cancer Res. CR. 42, 260 (2023).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"86979_CR27","doi-asserted-by":"publisher","first-page":"109429","DOI":"10.1016\/j.celrep.2021.109429","volume":"36","author":"BM Larsen","year":"2021","unstructured":"Larsen, B. M. et al. A pan-cancer organoid platform for precision medicine. Cell. Rep. 36, 109429 (2021).","journal-title":"Cell. Rep."},{"key":"86979_CR28","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1073\/pnas.1015938108","volume":"108","author":"J Kondo","year":"2011","unstructured":"Kondo, J. et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl. Acad. Sci. U S A. 108, 6235\u20136240 (2011).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"86979_CR29","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.devcel.2023.04.012","volume":"58","author":"W Senkowski","year":"2023","unstructured":"Senkowski, W. et al. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Dev. Cell. 58, 1106\u20131121e7 (2023).","journal-title":"Dev. Cell."},{"key":"86979_CR30","doi-asserted-by":"crossref","unstructured":"de Serio, P. A. et al. M. P. Somatic mutational profile of high-grade serous ovarian carcinoma and triple-negative breast carcinoma in young and elderly patients: Similarities and divergences. Cells 10 (2021).","DOI":"10.3390\/cells10123586"},{"key":"86979_CR31","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1186\/s12885-022-09727-6","volume":"22","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. The genomic and transcriptome characteristics of lung adenocarcinoma patients with previous breast cancer. BMC Cancer. 22, 618 (2022).","journal-title":"BMC Cancer"},{"key":"86979_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40246-018-0170-6","volume":"12","author":"T Hu","year":"2018","unstructured":"Hu, T. et al. Forward and reverse mutations in stages of cancer development. Hum. Genomics. 12, 40 (2018).","journal-title":"Hum. Genomics"},{"key":"86979_CR33","doi-asserted-by":"crossref","unstructured":"Rao, X. et al. Unveiling epigenetic vulnerabilities in triple-negative breast cancer through 3D organoid drug screening. Pharm. Basel Switz. 17 (2024).","DOI":"10.3390\/ph17020225"},{"key":"86979_CR34","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1158\/2159-8290.CD-23-0050","volume":"13","author":"HF Farin","year":"2023","unstructured":"Farin, H. F. et al. Colorectal cancer organoid-stroma biobank allows subtype-specific assessment of individualized therapy responses. Cancer Discov. 13, 2192\u20132211 (2023).","journal-title":"Cancer Discov."},{"key":"86979_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","volume":"3","author":"KP Guillen","year":"2022","unstructured":"Guillen, K. P. et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat. Cancer. 3, 232\u2013250 (2022).","journal-title":"Nat. Cancer"},{"key":"86979_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","volume":"20","author":"M McLaughlin","year":"2020","unstructured":"McLaughlin, M. et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer. 20, 203\u2013217 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"86979_CR37","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni, D., Angell, H. K. & Galon, J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer. 20, 662\u2013680 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"86979_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer. 20, 174\u2013186 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"86979_CR39","doi-asserted-by":"crossref","unstructured":"Barrett, R. L. & Pur\u00e9, E. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. eLife 9 (2020).","DOI":"10.7554\/eLife.57243"},{"key":"86979_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","volume":"24","author":"R Polak","year":"2024","unstructured":"Polak, R., Zhang, E. T. & Kuo, C. J. Cancer organoids 2.0: Modelling the complexity of the tumour immune microenvironment. Nat. Rev. Cancer. 24, 523\u2013539 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"86979_CR41","doi-asserted-by":"publisher","first-page":"26580","DOI":"10.1073\/pnas.1911273116","volume":"116","author":"E Driehuis","year":"2019","unstructured":"Driehuis, E. et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc. Natl. Acad. Sci. U S A. 116, 26580\u201326590 (2019).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"86979_CR42","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.stem.2021.03.012","volume":"28","author":"K L\u00f5hmussaar","year":"2021","unstructured":"L\u00f5hmussaar, K. et al. Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer. Cell. Stem Cell. 28, 1380\u20131396e6 (2021).","journal-title":"Cell. Stem Cell."},{"key":"86979_CR43","unstructured":"Sachs, N. et al. Long-term expanding human airway organoids for disease modeling. EMBO J 38  (2019)."},{"key":"86979_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-023-01919-3","volume":"23","author":"T Schm\u00e4che","year":"2024","unstructured":"Schm\u00e4che, T. et al. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold. Mol. Cancer. 23, 10 (2024).","journal-title":"Mol. Cancer"},{"key":"86979_CR45","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","volume":"141","author":"T Sato","year":"2011","unstructured":"Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett\u2019s epithelium. Gastroenterology 141, 1762\u20131772 (2011).","journal-title":"Gastroenterology"},{"key":"86979_CR46","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.stem.2017.12.009","volume":"22","author":"T Seino","year":"2018","unstructured":"Seino, T. et al. Human pancreatic tumor Organoids Reveal loss of stem cell niche factor dependence during Disease Progression. Cell. Stem Cell. 22, 454\u2013467e6 (2018).","journal-title":"Cell. Stem Cell."},{"key":"86979_CR47","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.stem.2018.09.016","volume":"23","author":"HHN Yan","year":"2018","unstructured":"Yan, H. H. N. et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell. Stem Cell. 23, 882\u2013897e11 (2018).","journal-title":"Cell. Stem Cell."},{"key":"86979_CR48","doi-asserted-by":"publisher","first-page":"101335","DOI":"10.1016\/j.xcrm.2023.101335","volume":"4","author":"T Tan","year":"2023","unstructured":"Tan, T. et al. Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer. Cell. Rep. Med. 4, 101335 (2023).","journal-title":"Cell. Rep. Med."},{"key":"86979_CR49","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920\u2013926 (2018).","journal-title":"Science"},{"key":"86979_CR50","doi-asserted-by":"crossref","unstructured":"Yin, S. et al. Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Sci. Transl. Med. 12 (2020).","DOI":"10.1126\/scitranslmed.aaz1723"},{"key":"86979_CR51","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","volume":"30","author":"AM De La Acanda","year":"2024","unstructured":"De La Acanda, A. M. et al. Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers. Nat. Med. 30, 990\u20131000 (2024).","journal-title":"Nat. Med."},{"key":"86979_CR52","doi-asserted-by":"publisher","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","volume":"11","author":"SN Ooft","year":"2019","unstructured":"Ooft, S. N. et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci. Transl. Med. 11, eaay2574 (2019).","journal-title":"Sci. Transl. Med."},{"key":"86979_CR53","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"184","author":"S Raghavan","year":"2021","unstructured":"Raghavan, S. et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 184, 6119\u20136137e26 (2021).","journal-title":"Cell"},{"key":"86979_CR54","doi-asserted-by":"publisher","first-page":"105962","DOI":"10.1016\/j.isci.2023.105962","volume":"26","author":"R Coppo","year":"2023","unstructured":"Coppo, R. et al. Distinct but interchangeable subpopulations of colorectal cancer cells with different growth fates and drug sensitivity. iScience 26, 105962 (2023).","journal-title":"iScience"},{"key":"86979_CR55","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s42003-021-02607-y","volume":"4","author":"Y Hirokawa","year":"2021","unstructured":"Hirokawa, Y. et al. Low-viscosity matrix suspension culture enables scalable analysis of patient-derived organoids and tumoroids from the large intestine. Commun. Biol. 4, 1067 (2021).","journal-title":"Commun. Biol."},{"key":"86979_CR56","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1038\/s41598-022-09508-y","volume":"12","author":"S Price","year":"2022","unstructured":"Price, S. et al. A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens. Sci. Rep. 12, 5571 (2022).","journal-title":"Sci. Rep."},{"key":"86979_CR57","doi-asserted-by":"publisher","first-page":"10412","DOI":"10.1038\/s41598-023-35657-9","volume":"13","author":"JY Co","year":"2023","unstructured":"Co, J. Y., Klein, J. A., Kang, S. & Homan, K. A. Suspended hydrogel culture as a method to scale up intestinal organoids. Sci. Rep. 13, 10412 (2023).","journal-title":"Sci. Rep."},{"key":"86979_CR58","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202312.2280.v1","author":"L Ismail","year":"2023","unstructured":"Ismail, L. et al. Patient-derived free-floating non-small cell lung cancer organoids: A versatile tool for personalized testing of chemotherapeutic drugs. Preprints https:\/\/doi.org\/10.20944\/preprints202312.2280.v1 (2023).","journal-title":"Preprints"},{"key":"86979_CR59","doi-asserted-by":"publisher","first-page":"1553477","DOI":"10.1080\/2162402X.2018.1553477","volume":"8","author":"JM Ayuso","year":"2019","unstructured":"Ayuso, J. M. et al. Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. Oncoimmunology 8, 1553477 (2019).","journal-title":"Oncoimmunology"},{"key":"86979_CR60","doi-asserted-by":"crossref","unstructured":"Poggi, A. et al. Three-dimensional culture models to study innate anti-tumor immune response: Advantages and disadvantages. Cancers 13  (2021).","DOI":"10.3390\/cancers13143417"},{"key":"86979_CR61","doi-asserted-by":"crossref","unstructured":"Magr\u00e9, L. et al. Emerging organoid-immune co-culture models for cancer research: From oncoimmunology to personalized immunotherapies. J. Immunother. Cancer 11  (2023).","DOI":"10.1136\/jitc-2022-006290"},{"key":"86979_CR62","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","volume":"174","author":"KK Dijkstra","year":"2018","unstructured":"Dijkstra, K. K. et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174, 1586\u20131598e12 (2018).","journal-title":"Cell"},{"key":"86979_CR63","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth, C. et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 12, 372\u2013387 (2022).","journal-title":"Cancer Discov"},{"key":"86979_CR64","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41698-023-00480-y","volume":"7","author":"M Le Compte","year":"2023","unstructured":"Le Compte, M. et al. Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. NPJ Precis. Oncol. 7, 128 (2023).","journal-title":"NPJ Precis. Oncol."},{"key":"86979_CR65","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1158\/1078-0432.CCR-20-0073","volume":"26","author":"V Narasimhan","year":"2020","unstructured":"Narasimhan, V. et al. Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy. Clin. Cancer Res. 26, 3662\u20133670 (2020).","journal-title":"Clin. Cancer Res."},{"key":"86979_CR66","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13046-023-02683-4","volume":"42","author":"LH Jensen","year":"2023","unstructured":"Jensen, L. H. et al. Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: A phase 2, single-center, open-label, and non-comparative study. J. Exp. Clin. Cancer Res. CR. 42, 115 (2023).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"86979_CR67","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani, D. et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 12, 388\u2013401 (2022).","journal-title":"Cancer Discov"},{"key":"86979_CR68","doi-asserted-by":"crossref","unstructured":"Mauri, G. et al. Empowering clinical decision making in oligometastatic colorectal cancer: The potential role of drug screening of patient-derived organoids. JCO Precis. Oncol. 5, PO.21.00143 (2021).","DOI":"10.1200\/PO.21.00143"},{"key":"86979_CR69","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.ccell.2022.09.017","volume":"40","author":"S Bose","year":"2022","unstructured":"Bose, S. et al. A path to translation: How 3D patient tumor avatars enable next generation precision oncology. Cancer Cell. 40, 1448\u20131453 (2022).","journal-title":"Cancer Cell."},{"key":"86979_CR70","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-022-00356-6","volume":"10","author":"MA Foo","year":"2022","unstructured":"Foo, M. A. et al. Clinical translation of patient-derived tumour organoids- bottlenecks and strategies. Biomark. Res. 10, 10 (2022).","journal-title":"Biomark. Res."},{"key":"86979_CR71","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41571-023-00745-2","volume":"20","author":"AWJ van Renterghem","year":"2023","unstructured":"van Renterghem, A. W. J., van de Haar, J. & Voest, E. E. Functional precision oncology using patient-derived assays: Bridging genotype and phenotype. Nat. Rev. Clin. Oncol. 20, 305\u2013317 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"86979_CR72","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"86979_CR73","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","volume":"36","author":"SX Ge","year":"2020","unstructured":"Ge, S. X., Jung, D. & Yao, R. ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinform. Oxf. Engl. 36, 2628\u20132629 (2020).","journal-title":"Bioinform. Oxf. Engl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86979-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86979-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86979-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T10:40:14Z","timestamp":1738320014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86979-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["86979"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-86979-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.10.598331","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are current or former employees of and have received compensation from Thermo Fisher Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3933"}}